Anda Vlad, M.D., Ph.D.

Anda Vlad, M.D., Ph.D., serves as a Program Director in the Chemopreventive Agent Development Research Group (CADRG), Division of Cancer Prevention (DCP), National Cancer Institute (NCI).

Dr. Vlad has expertise in the field of cancer immunology with a focus on immune surveillance in premalignancy and malignancy, immune therapy development, and identification of immune biomarkers of response.

Before joining DCP in October 2023, she was a tenured Associate Professor in the Department of Obstetrics, Gynecology and Reproductive Sciences at the University of Pittsburgh School of Medicine and Principal Investigator at the Magee-Womens Research Institute (MWRI). Her lab at MWRI focused on ovarian cancer biology, preclinical development of ovarian cancer mouse models using genetically engineered mice, and in vivo testing of new immunotherapy and immunoprevention protocols. Preclinical studies in her lab created the foundation for the design and implementation of several early phase ovarian cancer immunotherapy clinical trials. As Director of Translational Studies, Dr. Vlad and her group used multiplex tissue and blood profiling platforms to identify immune biomarkers of response in patients treated with new chemo-immunotherapy combinations.

At MWRI, Dr. Vlad served as the Director of the Summer Undergraduate Research Program and Scientific Director of Magee-Womens Research Institute Flow Cytometry and Multiplex Profiling Core. She is the recipient of the Pitt Innovator Award and of the DOD Ovarian Cancer Academy Career Development Award.

Dr. Vlad earned her M.D. from the University of Craiova School of Medicine in Romania and her Ph.D. in Immunology from the University of Pittsburgh School of Medicine.